{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:43:55Z","timestamp":1793403835269,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,6]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)\/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement with or without ascites is a poor prognostic factor in patients with dMMR\/MSI-H metastatic colorectal cancer (mCRC) and gastric cancer (mGC) receiving ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a global multicohort study at Tertiary Cancer Centers and collected clinic-pathological data from a cohort of patients with dMMR\/MSI-H mCRC treated with anti-PD-(L)1 \u00b1anti-CTLA-4 agents at 12 institutions (developing set). A cohort of patients with dMMR\/MSI-high mGC treated with anti-PD-1 agents\u00b1chemotherapy at five institutions was used as validating dataset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mCRC cohort included 502 patients. After a median follow-up of 31.2 months, patients without peritoneal metastases and those with peritoneal metastases and no ascites had similar outcomes (adjusted HR (aHR) 1.15, 95% CI 0.85 to 1.56 for progression-free survival (PFS); aHR 0.96, 95% CI 0.65 to 1.42 for overall survival (OS)), whereas inferior outcomes were observed in patients with peritoneal metastases and ascites (aHR 2.90, 95% CI 1.70 to 4.94; aHR 3.33, 95% CI 1.88 to 5.91) compared with patients without peritoneal involvement. The mGC cohort included 59 patients. After a median follow-up of 17.4 months, inferior PFS and OS were reported in patients with peritoneal metastases and ascites (aHR 3.83, 95% CI 1.68 to 8.72; aHR 3.44, 95% CI 1.39 to 8.53, respectively), but not in patients with only peritoneal metastases (aHR 1.87, 95% CI 0.64 to 5.46; aHR 2.15, 95% CI 0.64 to 7.27) when compared with patients without peritoneal involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with dMMR\/MSI-H gastrointestinal cancers with peritoneal metastases and ascites should be considered as a peculiar subgroup with highly unfavorable outcomes to current ICI-based therapies. Novel strategies to target the immune-suppressive niche in malignant effusions should be investigated, as well as next-generation ICIs or intraperitoneal approaches.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004001","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:26:25Z","timestamp":1643797585000},"page":"e004001","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":117,"title":["Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02997228","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04008030","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-2253","authenticated-orcid":false,"given":"Giovanni","family":"Fuc\u00e0","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-5162","authenticated-orcid":false,"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Department of Medical Oncology, H\u00f4pital Saint-Antoine, AP-HP and INSERM, Unit\u00e9 Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilit\u00e9 des Microsatellites et Cancer, Equipe labellis\u00e9e par la Ligue Nationale contre le Cancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Medical Oncology 3 and Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Elez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-504X","authenticated-orcid":false,"given":"Joseph","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J","family":"Klempner","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Emmett","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jayachandran","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D\u00edez","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mazzoli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Provenzano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Colle","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Department of Medical Oncology, H\u00f4pital Saint-Antoine, AP-HP and INSERM, Unit\u00e9 Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilit\u00e9 des Microsatellites et Cancer, Equipe labellis\u00e9e par la Ligue Nationale contre le Cancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Department of Pathology, H\u00f4pital Saint-Antoine, AP-HP, and INSERM, Unit\u00e9 Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilit\u00e9 des Microsatellites et Cancer, Equipe labellis\u00e9e par la Ligue Nationale contre le Cancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash Tushar","family":"Shah","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Salati","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, PhD Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fenocchio","sequence":"additional","affiliation":[{"name":"Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Chida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Conca","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"},{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"European Institute of Oncology (IEO), IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Corti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"},{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andre","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Department of Medical Oncology, H\u00f4pital Saint-Antoine, AP-HP and INSERM, Unit\u00e9 Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilit\u00e9 des Microsatellites et Cancer, Equipe labellis\u00e9e par la Ligue Nationale contre le Cancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"2025100304413850000_10.2.e004001.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100304413850000_10.2.e004001.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2025100304413850000_10.2.e004001.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"2025100304413850000_10.2.e004001.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"key":"2025100304413850000_10.2.e004001.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2025100304413850000_10.2.e004001.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"2025100304413850000_10.2.e004001.7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: pooled results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"JCO"},{"key":"2025100304413850000_10.2.e004001.8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100304413850000_10.2.e004001.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"2025100304413850000_10.2.e004001.10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","article-title":"Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"144","author":"Colle","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100304413850000_10.2.e004001.11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100304413850000_10.2.e004001.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz134"},{"key":"2025100304413850000_10.2.e004001.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-ITI11-1"},{"key":"2025100304413850000_10.2.e004001.14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2021.03.043","article-title":"The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors","volume":"150","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100304413850000_10.2.e004001.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0590-4"},{"key":"2025100304413850000_10.2.e004001.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.05.010"},{"key":"2025100304413850000_10.2.e004001.17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2021.05.006","article-title":"Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity","volume":"39","author":"Chow","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100304413850000_10.2.e004001.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116"},{"key":"2025100304413850000_10.2.e004001.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025100304413850000_10.2.e004001.20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/annonc\/mdw627","article-title":"Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the colon life nomogram","volume":"28","author":"Pietrantonio","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100304413850000_10.2.e004001.21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000491753","article-title":"Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: the gastric life nomogram","volume":"95","author":"Pietrantonio","year":"2018","journal-title":"Oncology"},{"key":"2025100304413850000_10.2.e004001.22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","article-title":"Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities","volume":"2","author":"Tanaka","year":"2021","journal-title":"Nat Cancer"},{"key":"2025100304413850000_10.2.e004001.23","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496"},{"key":"2025100304413850000_10.2.e004001.24","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00432-020-03262-2","article-title":"Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France","volume":"146","author":"Aarnink","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100304413850000_10.2.e004001.25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2021.03.015","article-title":"Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): the pluie study","volume":"155","author":"Epaillard","year":"2021","journal-title":"Lung Cancer"},{"key":"2025100304413850000_10.2.e004001.26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden","volume":"25","author":"Pietrantonio","year":"2020","journal-title":"Oncologist"},{"key":"2025100304413850000_10.2.e004001.27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002501"},{"key":"2025100304413850000_10.2.e004001.28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003370"},{"key":"2025100304413850000_10.2.e004001.29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fonc.2021.672747","article-title":"Malignant pleural effusions-A window into local anti-tumor T cell immunity?","volume":"11","author":"Principe","year":"2021","journal-title":"Front Oncol"},{"key":"2025100304413850000_10.2.e004001.30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100304413850000_10.2.e004001.31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318070"},{"key":"2025100304413850000_10.2.e004001.32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite Instability-High gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:41:46Z","timestamp":1759491706000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,2]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/jitc-2021-004001"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004001","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}